Clinical trial · Observational
Comparison of the Therapeutic Efficacy of Non-touch Microwave Ablation, Tumor-puncture Microwave Ablation and Surgical Resection for Subcapsular Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Subcapsular hepatocellular carcinoma (HCC) has unique anatomical characteristics that may influence treatment selection and clinical outcomes. Surgical resection and liver transplantation are potentially curative treatments but may be limited by liver function, tumor characteristics, and perioperative risks. Microwave ablation has become an important minimally invasive treatment option for patients with HCC, particularly for lesions that are difficult to treat surgically. This prospective observational cohort study aims to compare the therapeutic efficacy, safety, and long-term outcomes of no-touch microwave ablation, tumor-puncture microwave ablation and surgical resection in patients with subcapsular HCC. Treatment outcomes, including local tumor control, treatment-related complications, recurrence, and survival outcomes, will be evaluated to provide evidence for individualized treatment strategies for patients with subcapsular HCC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma (HCC) | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No-touch Microwave Ablation | Procedure | — | UNRESOLVED |
| Surgical Resection | Procedure | — | UNRESOLVED |
| Tumor-puncture Microwave Ablation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- No-touch Microwave Ablation Cohort
- description
- Eligible patients meeting the inclusion criteria, including those with subcapsular hepatocellular carcinoma within Milan criteria, who receive ultrasound-guided percutaneous non-contact microwave ablation as part of routine clinical practice will be included in this cohort. In this treatment modality, the ablation antenna is positioned in the normal liver parenchyma surrounding the tumor rather than directly puncturing the lesion. Tumor inactivation is achieved through microwave thermal radiation. Clinical outcomes, including local tumor control, recurrence, treatment-related complications, and survival outcomes, will be evaluated during follow-up.
- interventionNames
- Procedure: No-touch Microwave Ablation
- label
- Tumor-puncture Microwave Ablation Cohort
- description
- Patients with subcapsular hepatocellular carcinoma who meet the inclusion criteria and receive conventional ultrasound-guided percutaneous contact microwave ablation with direct tumor puncture as part of routine clinical practice will be included in this cohort. In this treatment modality, the microwave ablation antenna is directly inserted into the tumor under ultrasound guidance, and tumor necrosis is achieved through microwave thermal effects. During the study period, patients will be followed up to evaluate local tumor control, recurrence, treatment-related complications, and survival outcomes.
- interventionNames
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Diagnosed with hepatocellular carcinoma (HCC) confirmed by pathological biopsy or clinical diagnostic criteria; Imaging examinations including ultrasound confirm that the HCC lesion is subcapsular, defined as the minimum distance between the tumor and liver capsule ≤ 3 mm; Single tumor with maximum diameter ≤ 5 cm, or up to 3 multiple tumors each with maximum diameter ≤ 3 cm; Liver function classified as Child-Pugh grade A or B; No invasion of adjacent blood vessels or vital organs; no tumor thrombus in the main portal vein or hepatic vein, and no extrahepatic metastasis. \- Exclusion Criteria:Patients with dysfunction of vital organs such as heart and lungs; Patients who received preoperative radiotherapy, chemotherapy, targeted therapy or immunotherapy, or patients complicated with other malignant tumors; Poor follow-up compliance and inability to complete the standardized follow-up procedures. \-
References
Publications (0)
Data not yet available